Related Experiment Video

Updated: Apr 3, 2026

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

1.4K

CDK4/6 inhibitor suppresses gastric cancer with CDKN2A mutation

Shiliang Huang1, Hua Ye1, Wenying Guo1

  • 1Department of Gastroenterology, Ningbo Medical Treatment Center Lihuili Hospital Ningbo 315040, Zhejiang, China.

International Journal of Clinical and Experimental Medicine
|September 18, 2015
PubMed
Abstract

Insights

Gastric cancer with CDKN2A mutations shows sensitivity to CDK4/6 inhibitors. The compound PD-0332991 effectively inhibits cancer cell proliferation and progression, offering a potential targeted therapy.

Area of Science:

  • Oncology
  • Genomics
  • Pharmacology

Background:

  • Gastric cancer presents a significant global health challenge with limited long-term treatment efficacy.
  • There is a critical need for targeted therapies tailored to the specific genetic profiles of gastric tumors.

Purpose of the Study:

  • To identify actionable genetic targets in gastric cancer.
  • To evaluate the therapeutic potential of CDK4/6 inhibitors against gastric cancer with specific mutations.

Main Methods:

  • Utilized The Cancer Genomic Atlas (TCGA) and Genomics of Drug Sensitivity in Cancer (GDSC) databases for in silico analysis.
  • Conducted in vitro experiments to validate computational findings, including cell proliferation, invasion, migration, and colony formation assays.
  • Assessed the efficacy of PD-0332991 in a xenograft gastric cancer mouse model.

Main Results:

  • Identified CDKN2A as a frequently mutated gene in gastric cancer via TCGA.
  • GDSC data indicated sensitivity of cancer cells with CDKN2A mutations to the CDK4/6 inhibitor PD-0332991.
  • In vitro studies confirmed that PD-0332991 selectively inhibits proliferation, invasion, migration, and colony formation in gastric cancer cells with CDKN2A mutations, inducing cell cycle arrest.
  • PD-0332991 demonstrated efficacy in inhibiting tumor growth in a gastric cancer xenograft mouse model.

Conclusions:

  • Gastric cancer harboring CDKN2A mutations exhibits sensitivity to CDK4/6 inhibition.
  • PD-0332991 emerges as a promising therapeutic candidate for treating gastric cancer with CDKN2A mutations.
Keywords:
CDK4/6CDKN2AGastric cancercell cycle

More Related Videos

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.9K
Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT10:28

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

11.7K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.2K
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

5.7K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
6.8K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
10.1K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

3.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K